

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November 13, 2018.

Commission File Number: **001-38524**

Titan Medical Inc.

(Exact Name of Registrant as Specified in Charter)

**170 University Avenue, Suite 1000
Toronto, Ontario M5H 3B3
Canada**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): X

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TITAN MEDICAL INC.
(Registrant)

Date: November 13, 2018

By: /s/ Stephen Randall
Name: Stephen Randall
Title: Chief Financial Officer

TITAN MEDICAL INC.
Unaudited Condensed Interim Financial Statements
Three and Nine Months Ended September 30, 2018 and 2017

(IN UNITED STATES DOLLARS)

TITAN MEDICAL INC.
Unaudited Condensed Interim Balance Sheets
As at September 30, 2018 and December 31, 2017
(In U.S. Dollars)

	Note	September 30, 2018	December 31, 2017
Assets			
Current Assets:			
Cash and cash equivalents		\$ 29,230,819	\$ 26,130,493
Amounts receivable		111,150	75,151
Deposits	6	4,278,850	2,538,434
Prepaid expense		636,542	149,593
Total Current Assets		\$ 34,257,361	\$ 28,893,671
Furniture and Equipment		-	6,714
Patent Rights	3	956,360	774,225
Total Assets		\$ 35,213,721	\$ 29,674,610
Liabilities			
Current Liabilities:			
Accounts payable and accrued liabilities		\$ 4,439,591	\$ 2,218,352
Warrant liability	2b, 5	18,749,143	17,849,460
Total Liabilities		23,188,734	20,067,812
Shareholders' Equity			
Share Capital	4a	170,253,262	154,016,519
Contributed Surplus		6,298,717	5,146,784
Warrants	4b	-	741,917
Deficit		(164,526,992)	(150,298,422)
Total Equity		12,024,987	9,606,798
Total liabilities and equity		\$ 35,213,721	\$ 29,674,610

Commitments (Note 6)
See notes to financial statements

Approved on behalf of the Board:

John E. Barker
Chairman

David McNally
President and CEO

TITAN MEDICAL INC.
Unaudited Condensed Interim Statement of Shareholders' Equity and Deficit
For the Periods Ended September 30, 2018 and 2017
(In U.S. Dollars)

	Share Capital Number	Share Capital Amount	Contributed Surplus	Warrants	Deficit	Total Equity
Balance - December 31, 2016	5,550,382	\$ 112,742,810	\$ 3,707,432	\$ 855,800	\$ (116,711,438)	\$ 594,604
Issued pursuant to agency agreement	2,699,094	12,547,765				12,547,765
Issued private placement	563,067	1,887,411				1,887,411
Warrant liability issued during the period		(4,661,928)				(4,661,928)
Share issue expense		(926,709)				(926,709)
Warrants exercised during the period	529,251	5,020,022				5,020,022
Warrants expired during the period		113,883		(113,883)		-
Stock based compensation			1,024,574			1,024,574
Net and Comprehensive loss for the period					(20,757,004)	(20,757,004)
Balance - September 30, 2017	9,341,794	\$ 126,723,254	\$ 4,732,006	\$ 741,917	\$ (137,468,442)	\$ (5,271,265)
Balance - December 31, 2017	12,686,723	154,016,519	5,146,784	741,917	(150,298,422)	9,606,798
Issued pursuant to agency agreement	8,975,126	28,424,732				28,424,732
Warrant liability issued during the period		(11,509,338)				(11,509,338)
Share issue expense		(1,546,800)				(1,546,800)
Issued Other	7,500	66,234				66,234
Warrants exercised during the period	6,500	59,998				59,998
Warrants expired during the period		741,917		(741,917)		-
Stock based compensation			1,151,933			1,151,933
Net and Comprehensive loss for the period					(14,228,570)	(14,228,570)
Balance - September 30, 2018	21,675,849	\$ 170,253,262	\$ 6,298,717	\$ -	\$ (164,526,992)	\$ 12,024,987

See notes to financial statements

TITAN MEDICAL INC.
Unaudited Condensed Interim Statement of Net and Comprehensive Loss
For the Three and Nine Months Ended September 30, 2018 and 2017
(In U.S. Dollars)

	Note	Three months ended September 30,		Nine months ended September 30,	
		2018	2017	2018	2017
Revenue:		\$ -	\$ -	\$ -	\$ -
Expenses:					
Amortization		5,371	2,527	22,485	13,312
Consulting fees		134,009	132,753	505,197	403,186
Stock based compensation	4(b)	428,528	400,892	1,151,933	1,024,574
Insurance		120,434	5,533	136,391	18,997
Management salaries and fees		622,910	623,819	2,062,909	1,870,574
Marketing and investor relations		55,395	77,479	226,393	243,316
Office and general		110,106	55,060	344,733	222,561
Professional fees		142,299	80,507	466,766	377,157
Rent		23,602	26,974	73,395	77,228
Research and Development		9,143,987	4,061,695	18,664,336	9,712,072
Travel		64,430	67,251	250,327	224,627
Foreign exchange (gain)/loss		286,152	194,157	(646,245)	274,721
		11,137,223	5,728,647	23,258,620	14,462,325
Finance Income (cost):					
Interest		93,894	3,356	176,877	8,764
Gain (Loss) on change in fair value of warrants	2(b), 5	4,075,833	(8,099,030)	9,928,944	(5,726,557)
Warrant liability issue cost		(566,960)	(78,496)	(1,075,771)	(576,886)
		3,602,767	(8,174,170)	9,030,050	(6,294,679)
Net and Comprehensive Loss		\$ 7,534,456	\$ 13,902,817	\$ 14,228,570	\$ 20,757,004
Basic and Diluted Loss Per Share		\$ 0.41	\$ 1.65	\$ 0.95	\$ 3.05
Weighted Average Number of Common Shares, Basic and Diluted		18,253,430	8,410,063	14,936,375	6,800,328

See notes to financial statements

TITAN MEDICAL INC.
Unaudited Condensed Interim Statements of Cash Flows
For the Three and Nine Months Ended September 30, 2018 and 2017
(In U.S. Dollars)

	Three months ending September 30,		Nine months ending September 30,	
	2018	2017	2018	2017
Cash provided by (used in):				
Operating activities:				
Net loss for the period	\$ (7,534,456)	\$ (13,902,817)	\$ (14,228,570)	\$ (20,757,004)
Items not involving cash:				
Amortization	5,371	2,527	22,485	13,312
Stock based compensation	428,528	400,892	1,151,933	1,024,574
Other share compensation	-	-	66,234	-
Warrant liability-fair value adjustment	(4,075,833)	7,389,248	(9,928,944)	5,016,775
Warrant liability-foreign exchange adjustment	283,894	170,553	(651,762)	221,742
Loss on extinguishment of other liabilities	-	709,782	-	709,782
Changes in non-cash working capital items:				
Amounts receivable, prepaid expenses and deposits	(444,935)	231,729	(2,263,365)	(496,957)
Accounts payable and accrued liabilities	250,756	(674,100)	2,221,239	701,473
Cash used in operating activities	(11,086,675)	(5,672,186)	(23,610,750)	(13,566,303)
Financing activities:				
Net proceeds from issuance of common shares and warrants	18,051,242	3,719,490	26,908,982	14,220,805
Cash provided by financing activities	18,051,242	3,719,490	26,908,982	14,220,805
Investing Activities:				
Increase in furniture and equipment	-	-	-	(3,427)
Cost of Patents	(100,867)	(81,943)	(197,906)	(187,267)
Cash used in investing activities	(100,867)	(81,943)	(197,906)	(190,694)
Increase (decrease) in cash and cash equivalents	6,863,700	(2,034,639)	3,100,326	463,808
Cash and cash equivalents, beginning of period	22,367,119	6,838,358	26,130,493	4,339,911
Cash and cash equivalents, end of period	\$ 29,230,819	\$ 4,803,719	\$ 29,230,819	\$ 4,803,719
Cash and cash equivalents comprise:				
Cash	\$ 261,935	\$ 2,556,533	\$ 261,935	\$ 2,556,533
Cash Equivalents	28,968,884	2,247,186	28,968,884	2,247,186
	\$ 29,230,819	\$ 4,803,719	\$ 29,230,819	\$ 4,803,719

See notes to financial statements

1. DESCRIPTION OF BUSINESS

Nature of Operations:

The Company's business continues to be in the research and development stage and is focused on the continued research and development of the next generation surgical robotic platform. In the near term, the Company will continue efforts to complete product development and proceed to pre-clinical and confirmatory human studies and satisfaction of appropriate regulatory requirements. Upon receipt of regulatory approvals, the Company will transition from the research and development stage to the commercialization stage. The completion of these latter stages will be subject to the Company receiving additional funding in the future.

The Company is incorporated in Ontario, Canada in accordance with the Business Corporations Act. The address of the Company's corporate office and its principal place of business is Toronto, Canada.

Basis of Preparation:

(a) Statement of Compliance

These condensed interim financial statements for the three and nine months ending September 30, 2018 have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting ("IAS 34").

These condensed interim financial statements should be read in conjunction with the Company's 2017 annual financial statements which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

The condensed interim financial statements have been prepared using accounting policies consistent with those used in the Company's 2017 annual financial statements as well as any amendments, revisions and new IFRS, which have been issued subsequently and are appropriate to the Company.

The condensed interim financial statements were authorized for issue by the Board of Directors on November 12, 2018.

(b) Basis of Measurement

These condensed interim financial statements have been prepared on the historical cost basis except for the revaluation of the warrant liability, which is measured at fair value.

(c) Functional and Presentation Currency

These condensed interim financial statements are presented in United States dollars ("U.S."), which is the Company's functional and presentation currency.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Use of Estimates and Judgements

The preparation of financial statements in conformity with IAS 34, Interim Financial Reporting requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of provisions at the date of the condensed interim financial statements and the reported amount of expenses during the year. Financial statement items subject to significant judgement include, the measurement of stock based compensation and the fair value estimate of the initial measurement of new warrant liabilities and the remeasurement of unlisted warrant liabilities. While management believes that the estimates and assumptions are reasonable, actual results may differ.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

In assessing whether the going concern assumption is appropriate, management considers all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. The Company expects that approximately US \$30 million in incremental funding is needed, for the next 12 months to maintain its currently anticipated pace of development. If additional funding is not available, the pace of the Company's product development plan may be reduced. However, based on internal forecasts, Management believes that the Company has sufficient funds to meet its obligations under a reduced development plan, if necessary, for the ensuing twelve months.

Fair Value

The Black-Scholes model used by the Company to determine fair values of stock options and warrants was developed for use in estimating the fair value of the stock options and warrants.

(b) Warrant Liability

In accordance with IAS 32, because the exercise prices of warrants issued are not a fixed amount as they are denominated in a currency (Canadian dollars) other than the Company's functional currency (U.S. dollar), as well as the warrants issued August 10, 2018 with the cashless exercise options, the warrants are accounted for as a derivative financial liability. Each Warrant Liability is initially measured at fair value and subsequent changes in fair value are recorded through Net and Comprehensive Loss for the year. The fair value of these warrants was determined initially using a comparable warrant quoted in an active market, adjusted for differences in the terms of the warrant. At September 30, 2018, the Warrant Liability of listed warrants was adjusted to fair value measured at the market price of the listed warrants, the unlisted warrants were adjusted to fair value using the Black-Scholes formula.

(c) Fair Value Measurement

The accounting guidance for fair value measurements prioritizes the inputs used in measuring fair value into the following hierarchy:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are directly or indirectly observable;

Level 3 – Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

The fair value of the listed and unlisted Warrant liability is initially based on level 2 significant observable inputs and at September 30, 2018 is based on level 1, quoted prices (unadjusted) for listed warrants and level 2 for unlisted warrants.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

New accounting standards applied

IFRS 9 Financial Instruments

Effective January 1, 2018, the Company adopted IFRS 9, "Financial Instruments", which replaced IAS 39, "Financial Instruments: Recognition and Measurement". The adoption of IFRS 9 did not have a material impact on the measurement and carrying values of the Company's financial instruments, including cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and warrant liability.

3. PATENT RIGHTS

Cost

Balance at December 31, 2017	\$ 978,126
Additions	<u>197,906</u>
Balance at September 30, 2018	\$ <u>1,176,032</u>

Amortization

Balance at December 31, 2017	\$ 203,901
Amortization for the period	<u>15,771</u>
Balance at September 30, 2018	\$ <u>219,672</u>

Net Book Value

At December 31, 2017	\$ <u>774,225</u>
At September 30, 2018	\$ <u>956,360</u>

4. SHARE CAPITAL

a) Authorized:	unlimited number of common shares, no par
Issued:	21,675,849 (December 31, 2017: 12,686,723)

Exercise prices of units, warrants and options are presented in Canadian currency as they are exercisable in Canadian dollars unless otherwise noted.

On June 19, 2018 a share consolidation of 1:30 was completed and the Company's outstanding common shares were adjusted from 419,888,250 to 13,996,275. All references to the common shares, warrants and stock options, prior to the share consolidation, have been updated in the notes to reflect the 1:30 reverse stock split.

On August 10, 2018 Titan Completed an offering of securities made pursuant to an agency agreement dated August 7, 2018 between the Company and Bloom Burton Securities Inc. (the "Agent"). The Company sold 7,679,574 Units under the Offering price of US \$2.50 per Unit for gross proceeds of approximately \$19,198,935 (\$17,470,398 net of closing cost including cash commission of \$1,343,925). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of US \$3.20 and expiring August 10, 2023. The warrants were valued at \$6,297,251 based on the value determined by the Black-Scholes model and the balance of \$12,901,684 was allocated to common shares.

4. SHARE CAPITAL (continued)

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 537,570 Common Shares at a price of USD \$2.50 per share prior to expiry on August 10, 2020.

On April 10, 2018 Titan completed an offering of securities made pursuant to an agency agreement dated April 3, 2018 between the Company and Bloom Burton Securities Inc. The Company sold 1,126,665 Units under the Offering at a price of CDN \$9.00 per Unit for gross proceeds of approximately \$8,035,941 (\$7,211,320 net of closing costs including cash commission of \$562,516). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$10.50 and expiring April 10, 2023. The warrants were valued at \$4,553,700 based on the value determined by the Black-Scholes model and the balance of \$3,482,241 was allocated to common shares.

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 78,867 Common Shares at a price of CDN \$9.00 per share prior to expiry on April 10, 2020.

On May 10, 2018 Titan announced the completion of the over-allotment option granted to Bloom Burton Securities Inc. as agent for its offering at a price of CDN \$9.00 per Unit completed on April 10, 2018 was exercised and the Company sold an additional 168,889 Units at the offering price for additional gross proceeds of \$1,189,856 (\$1,100,238 net of closing costs including cash commission of \$76,988). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$10.50 and expiring April 10, 2023. The warrants were valued at \$658,387 based on the value determined by the Black-Scholes model and the balance of \$531,469 was allocated to common shares.

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 10,928 Common Shares at a price of CDN \$9.00 per share prior to expiry on April 10, 2020.

During the year ended December 31, 2017, 1,755,141 warrants had been exercised for total proceeds of \$9,438,577. The fair value of the exercised warrants had a value of \$7,953,581 which was reclassified from warrant liability to common stock.

On December 5, 2017 Titan completed an offering of securities made pursuant to an agency agreement dated November 30, 2017 between the Company and Bloom Burton Securities Inc. The company sold 1,533,333 Units under the Offering at a price of CDN \$15 per Unit for gross proceeds of approximately \$18,137,800 (\$16,555,875 net of closing costs including cash commission of \$1,246,185 paid in accordance with the terms of the agency agreement). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$18.00 and expiring December 5, 2022. The warrants were valued at \$5,223,686 based on the value determined by the Black-Scholes model and the balance of \$12,914,114 was allocated to common shares.

Pursuant to the agency agreement in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 105,350 Common Shares at a price of CDN \$15.00 per share prior to expiry on December 5, 2019.

4. SHARE CAPITAL (continued)

On October 31, 2017 Titan completed the final closing of a private placement led by a group of U.S. robotic surgeons. 446,197 common shares of Titan were issued at a subscription price of CDN \$7.50 per Common Share for gross proceeds of \$2,677,326.

On June 29, 2017 Titan completed an offering of securities made pursuant to an agency agreement dated June 26, 2017 between the Company and Bloom Burton Securities Inc. The Company sold 1,612,955 Units under the Offering at a price of CDN \$4.50 per Unit for gross proceeds of approximately \$5,576,357 (\$4,838,002 net of closing costs including cash commission of \$382,689 paid in accordance with the terms of the agency agreement). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$6.00 and expiring June 29, 2022. The warrants were valued at \$2,788,274 based on the value determined by the Black-Scholes model and the balance of \$2,788,083 was allocated to common shares.

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 109,533 Common Shares at a price of CDN \$4.50 per share prior to expiry on June 29, 2019.

On July 21, 2017 Titan completed a second closing of an offering of securities made pursuant to an agency agreement dated June 26, 2017 between the Company and Bloom Burton Securities Inc. The Company sold an additional 370,567 Units under the Offering at a price of CDN \$4.50 per Unit for gross proceeds of approximately \$1,328,871 (\$1,200,788 net of closing costs including cash commission of \$93,021 paid in accordance with the terms of the agency agreement). Each Unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitles the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$6.00 and expiring June 29, 2022. The warrants were valued at \$575,844 based on the value determined by the Black-Scholes model and the balance of \$753,027 was allocated to common shares.

Pursuant to the agency agreement in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 25,940 Common Share at a price of CDN \$4.50 per share prior to expiry on June 29, 2019.

On March 16, 2017 Titan completed an offering of securities made pursuant to an agency agreement dated March 10, 2017 between the Company and Bloom Burton Securities Inc. The Company sold 715,573 Units under the Offering at a price of CDN \$10.50 per Unit for gross proceeds of approximately \$5,642,537 (\$5,039,817 net of closing costs including cash commission of \$394,316 paid in accordance with the terms of the agency agreement). Each Unit consisted of one Common Share of the Company and (i) one-half of one Common Share purchase warrant, each whole warrant entitling the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$12.00 and expiring March 16, 2019, and (ii) one-half of one Common Share purchase warrant, each whole warrant entitling the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$15 and expiring March 16, 2021. The warrants were valued at \$1,297,810 based on the value determined by the Black-Scholes model and the balance of \$4,344,727 was allocated to common shares.

Pursuant to the agency agreement, in addition to the cash commission paid to the Agent, broker warrants were issued to the Agent which entitle the holder to purchase 50,005 Common Shares at a price of CDN \$10.50 per share prior to expiry on March 16, 2019.

4. **SHARE CAPITAL** (continued)

On November 23, 2015 Titan closed a private placement of 143,009 Common Shares to Longtai Medical Inc. at a subscription price of CDN \$36.90 per common share for gross proceeds of \$4,000,000. Under the Agreement, Titan granted to Longtai exclusive rights to negotiate an exclusive marketing, sales and distribution agreement for Titan's SPORT Surgical System in the Asia Pacific region. Longtai paid to Titan \$2,000,000 as a deposit toward the Distribution Agreement.

As the parties were not able to reach consensus as to the Distribution Agreement by the agreed upon date, the deposit became due for repayment to Longtai. On August 24, 2017 Titan completed a subscription agreement with Longtai for the equity conversion of Longtai's \$2.0 million deposit. Under the terms of the subscription agreement dated July 31, 2017, Titan issued to Longtai 563,067 Units at an assigned issue price of CDN \$4.50 per Unit. Each Unit consists of one common share and one common share purchase warrant, with each warrant exercisable for one Common Share at an exercise price of CDN \$6 per warrant and will expire August 24, 2022. The warrants were valued at \$822,372 based on the value determined by the Black-Scholes model.

The common shares were valued at \$1,887,411 based on the market value on August 24, 2017 of CDN \$4.20. The warrant and the common share were valued at fair value in accordance with International Financial Reporting Interpretations Committee Interpretation #19-Extinguishing Financial Liabilities ("IFRIC 19"). A loss of \$709,782 was incurred on extinguishment which is included in the Gain (Loss) on change in value of warrant liability in the statement of net and comprehensive loss.

b) Warrants, Stock Options and Compensation Options

Titan has reserved and set aside up to 10% of the issued and outstanding shares of Titan for granting of options to employees, officers, consultants and advisors. At September 30, 2018, 1,277,224 common shares (September 30, 2017: 371,240) were available for issue in accordance with the Company's stock option plan. The terms of these options are determined by the Board of Directors. A summary of the status of the Company's outstanding stock options as of September 30, 2018 and September 30, 2017 and changes during the periods ended on those dates is presented in the following table:

	Nine Months Ended September 30, 2018		Nine Months Ended September 30, 2017	
	Number of Stock Options	Weighted-average Exercise Price (CDN)	Number of Stock Options	Weighted-average Exercise Price (CDN)
Balance Beginning	591,609	\$ 21.30	240,075	\$ 33.00
Granted	322,517	\$ 13.51	366,161	\$ 15.68
Expired/Forfeited	(23,765)	\$ 17.36	(43,296)	\$ 34.93
Balance Ending	890,361	\$ 18.51	562,940	\$ 21.58

4. SHARE CAPITAL (continued)

The weighted-average remaining contractual life and weighted-average exercise price of options outstanding and of options exercisable as at September 30, 2018 are as follows:

Options Outstanding

Exercise Price (CDN)	Number Outstanding	Weighted-average remaining contractual life (years)	Options Exercisable
\$3.28	31,498	6.92	31,498
\$4.50	18,935	4.91	18,935
\$4.80	3,040	1.96	3,040
\$7.49	5,590	6.77	5,590
\$9.00	11,481	6.77	11,481
\$9.60	1,105	2.02	1,105
\$11.70	6,667	2.18	3,333
\$12.00	1,948	2.18	1,948
\$12.90	50,000	5.55	12,500
\$14.40	18,950	6.11	-
\$15.00	16,667	5.36	4,167
\$15.00	273,948	6.31	-
\$17.10	277,519	5.30	69,380
\$28.80	10,170	0.22	10,170
\$30.00	105,719	2.90	81,462
\$30.60	6,120	2.23	4,889
\$32.40	18,810	2.33	18,810
\$41.70	658	1.21	658
\$45.30	560	1.87	560
\$51.60	15,371	1.69	15,371
\$52.80	3,537	0.43	3,537
\$58.20	12,069	0.64	12,069
	890,361	5.10	310,503

The weighted average exercise price of options outstanding is CDN \$18.51 and CDN \$22.74 for options that are exercisable.

4. SHARE CAPITAL (continued)

Options are granted to Directors, Officers, Employees and Consultants at various times. Options are to be settled by physical delivery of shares.

Grant date/Person entitled	Number of Options	Vesting Conditions	Contractual life of Options
January 17, 2017, option grants to Employees	277,519	Vest as to 1/4 of the total number of Options granted, every year from Option Date	7 years
February 7, 2017 option grants to Employees	16,667	Vest as to 1/4 of the total number of Options granted, every year from Option Date	7 years
April 17, 2017, option grants to Employees	50,000	Vest as to 1/4 of the total number of Options granted, every year from Option Date	7 years
September 7, 2017, options granted to Consultants	6,667	Half vest in 3 months and the remaining half in 6 months	3 years
September 7, 2017, options granted to Directors	12,269	immediately	7 years
September 15, 2017, options granted to Consultants	3,040	immediately	3 years
October 6, 2017, options granted to Consultants	1,105	immediately	3 years
November 8, 2017 option grants to Employees	18,950	Vest as to 1/4 of the total number of Options granted, every year from Option Date	7 years
December 4, 2017, options granted to Consultants	1,948	immediately	3 years
December 4, 2017, options granted to Consultants	6,667	Half vest immediately and the remaining half in 12 months	3 years
January 19, 2018 option grants to Employees	273,948	Options will vest the earlier of commercialization or 3 years from grant date.	7 years
July 6, 2018, options granted to Directors	17,071	immediately	7 years
August 29, 2018, options granted to Directors	31,498	immediately	7 years

Inputs for Measurement of Grant Date Fair Values

The grant date fair value of all share-based payment plans was measured based on the Black-Scholes formula. Expected volatility was estimated by considering historic average share price volatility. The inputs used in the measurement of fair values at grant date of the share-based option plan are as follows:

	2018	2017
Fair Value at grant date (CDN)	\$1.44 - \$ 7.50	\$ 2.40 - \$ 9.60
Share price at grant date (CDN)	\$2.57 - \$13.80	\$ 4.50 - \$16.20
Exercise price (CDN)	\$3.28 - \$15.00	\$ 4.50 - \$17.10
Expected Volatility	88.1% - 96%	82.4% - 83.3%
Option Life	3 years	3 - 4 years
Expected dividends	nil	nil
Risk-free interest rate	1.86% - 2.16%	0.89% - 1.63%

TITAN MEDICAL INC.
Notes to the Unaudited Condensed Interim Financial Statements
Three and Nine Months Ended September 30, 2018
(In U.S. Dollars)

4. SHARE CAPITAL (continued)

The following is a summary of outstanding warrants included in Shareholder's Equity as at September 30, 2018 and September 30, 2017 and changes during the periods then ended.

	Nine Months Ended September 30, 2018		Nine Months Ended September 30, 2017	
	Number of Warrants	Amount	Number of Warrants	Amount
Opening Balance	5,260,705	\$ 741,917	5,651,434	\$ 855,800
Expired during the year Exercise Price CDN \$1.25 Expiry March 18, 2018	(5,260,705)	(741,917)	-	-
Expired during the year Exercise Price CDN \$1.77 Expiry March 14, 2017	-	-	(390,729)	(113,883)
Ending Balance	-	\$ -	5,260,705	\$ 741,917

5. WARRANT LIABILITY

	Nine Months Ended September 30, 2018		Year Ended December 31, 2017	
	Number of Warrants	Amount	Number of Warrants	Amount
Opening Balance	4,933,231	\$ 17,849,460	2,581,703	\$ 2,365,691
Issue of warrants expiring, March 16, 2019	-	-	357,787	572,326
Issue of warrants expiring, March 16, 2021	-	-	357,787	725,484
Issue of warrants expiring, June 29, 2022	-	-	1,983,522	3,364,118
Issue of warrants expiring, August 24, 2022	-	-	563,067	822,372
Issue of warrants expiring, December 5, 2022	-	-	1,533,333	5,223,686
Issue of warrants expiring, April 10, 2023	1,295,554	5,212,087	-	-
Issue of warrants expiring, August 10, 2023	7,679,574	6,297,251	-	-
Warrants exercised during the year	(6,500)	(28,949)	(1,755,142)	(7,953,581)
Warrants expired during the year	-	-	(688,826)	-
Foreign exchange adjustment during the year	-	(651,762)	-	305,475
Fair value adjustment during the year	-	(9,928,944)	-	12,423,889
Ending Balance	13,901,859	\$ 18,749,143	4,933,231	\$ 17,849,460

In addition to the warrants listed above, at September 30, 2018, the Company has issued and outstanding, 790,920 broker unit warrants expiring between October 27, 2018 and August 10, 2020.

TITAN MEDICAL INC.
Notes to the Unaudited Condensed Interim Financial Statements
Three and Nine Months Ended September 30, 2018
(In U.S. Dollars)

6. COMMITMENTS

The Company has 4,477 square feet leased at a former location for CDN \$4,673 per month through January 31, 2019. This space has been sublet for CDN \$4,099 per month through the lease term.

For its corporate office located at 170 University Avenue, Toronto Ontario, effective September 18, 2017 the Company extended its lease term for a period of 22 months, commencing February 1, 2018 at a monthly rent of CDN \$9,969.

As a part of its program of research and development around the SPORT Surgical System, the Company has outsourced certain aspects of the design and development to a U.S. based technology and development company. At September 30, 2018 \$14,490,933 in purchase orders remain outstanding. The Company also has on deposit with this same U.S. supplier \$4,278,850 to be applied against future invoices.

7. RELATED PARTY TRANSACTIONS

During the three months and nine months ended September 30, 2018, transactions between the Company and directors, officers and other related parties were related to compensation matters in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

Compensation to the Executive Officers amounted to \$322,792 and \$1,240,904 for the three and nine months ended September 30, 2018 compared to \$409,227 and \$1,165,759 for the same period in 2017.

Officers and Directors of the Company control approximately 0.25% of the Company

	September 30, 2018		December 31, 2017	
	Number of Shares	%	Number of Shares	%
John Barker	23,714	0.11	23,714	0.19
Martin Bernholtz	-	-	102,383	0.81
David McNally	4,167	0.02	1,667	0.01
Stephen Randall	18,243	0.08	11,910	0.09
John Schellhorn	294	-	294	-
Bruce Wolff	7,610	0.04	2,010	0.02
Total	54,028	0.25	141,978	1.12
Common Shares Outstanding	21,675,849	100 %	12,686,723	100 %

TITAN MEDICAL INC.
MANAGEMENT’S DISCUSSION AND ANALYSIS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018
(IN UNITED STATES DOLLARS)

This Management’s Discussion and Analysis (“MD&A”) is dated November 12, 2018.

This MD&A provides a review of the performance of Titan Medical Inc. (“Titan” or the “Company”) and should be read in conjunction with its unaudited condensed interim financial statements for the three and nine months ended September 30, 2018 (and the notes thereto) (the “Interim Financial Statements”). The Interim Financial Statements have been prepared in accordance with International Financial Reporting Standards 34, Interim Financial Reporting (“IAS 34”). All financial figures are in United States Dollars except where otherwise noted.

Internal Control over Financial Reporting

During the three and nine months ended September 30, 2018, no changes were made to the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Forward-Looking Statements

This discussion includes certain statements that may be deemed “forward-looking statements”. All statements in this discussion other than statements of historical facts that address future events, developments or transactions that the Company expects, are forward-looking statements. These forward-looking statements are made as of the date of this MD&A. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “expected”, “expectation”, “anticipates”, “believes”, “intends”, “estimates”, “predicts”, “potential”, “targeted”, “plans”, “possible”, “milestones”, “objectives” and similar expressions, or statements that events, conditions or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements that appear in this MD&A include:

- the Company is committed to developing its robotic surgical system with the objective of substantially improving upon minimally invasive surgery;
- the Company intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures;
- the SPORT Surgical System is being developed with the goal of inserting the interactive multi-articulating instruments and the 3D high definition vision system into the patient's body cavity through a single incision;
- our technology and research and development objectives and milestones, including such development milestones as completing the engineering confidence build and achieving design freeze, estimated costs, schedules for completion and probability of success;
- our intention with respect to updating any forward-looking statement after the date on which such statement is made or to reflect the occurrence of unanticipated events;
- our expectation with respect to continuing animal and human cadaver studies;
- our expectation that we can in a timely manner produce the appropriate preclinical and clinical data required for our 510(k) application to the U.S. Food and Drug Administration, and Technical File for the CE Mark;
- our expectation with respect to launching a commercial product in certain jurisdictions;
- our intentions to develop a robust training curriculum and post-training assessment tools;
- our plans to develop and commercialize the SPORT Surgical System and the estimated incremental costs (including the status, cost and timing of achieving the development milestones disclosed herein);
- our plans to design, create and refine software for production system functionality of the SPORT Surgical System and the estimated incremental costs (including the status, cost and timing of achieving the development milestones disclosed herein);
- our intentions to complete formative and summative human factors studies;
- our belief that existing and planned prototype units will be suitable to support human factors studies, preclinical evaluation and activities related to securing confirmatory human data during the remainder of 2018 and in 2019;
- our intentions with respect to initiating marketing activities following receipt of the applicable regulatory approvals;
- our intention to continue to assess specialized skill and knowledge requirements and recruitment of qualified personnel and partners;
- our belief that the materials and parts necessary for the manufacture of a clinical-grade SPORT Surgical System will be available in the marketplace;
- our intended use of proceeds of any offering of our securities;
- our intention with respect to not paying any cash dividends on Common Shares in the foreseeable future;
- our intention to retain future earnings, if any, to finance expansion and growth;
- our projected competitive conditions with respect to our products;
- our technology and research and development objectives, including such development milestones as completing the engineering confidence build and achieving design freeze, estimated costs, schedules for completion and probability of success;
- the Company continues to explore in-licensing opportunities for technologies that may be used in conjunction with the Company's robotic surgical system;
- the Company anticipates that it will continue its pursuit of key strategic relationships;
- the Company's continuing efforts to secure its intellectual property and expanding its patent portfolio by filing patent applications as it progresses in the development of robotic surgical technologies and by licensing suitable technologies;
- the Company's current plan is to focus on the development and commercialization of the SPORT Surgical System at estimated incremental costs and according to the timeline as set forth in the table below;
- the Company has decided to build additional prototypes and develop more advanced instruments and training systems for expanded use for additional surgical procedures;
- the Company intends to utilize a direct sales force and/or distribution partner(s) to initiate marketing the SPORT Surgical System to hospitals; and
- the Company's expectation that confirmatory human clinical data will be required for regulatory submissions.

Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are statements about the future and are inherently uncertain, and actual results of the Company or other future events or conditions may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors, such as current global financial conditions, dependence on key personnel, conflicts of interest, dependency on additional financing, our history of losses, reliance on strategic alliances, dependence on key personnel, the possibility of our inability to augment our management team when required, the possibility that our trade secrets and confidential information may be compromised, reliance on third parties for important aspects of our business, uncertainty as to product development and commercialization milestones, results of operations, competition, technological advancements, rapidly changing markets, uncertain market, uncertainty as to the enforceability of the Company's intellectual property, infringement of intellectual property rights of others, scope and cost of insurance and uninsured risks, risks associated with the Company entering into additional long-term contractual arrangements, ability to license other intellectual property rights, government regulation, changes in market conditions and demands and preferences, changes in government policy, exposure to product liability claims, changes in accounting and tax rules, regulatory inquiries, requirements and approvals, contingent liabilities, manufacturing and product defects, history of losses, stock price volatility, future share sales, limited operating history, fluctuating financial results and currency fluctuations, uncertainty as to our ability to meet our development and commercialization milestones, uncertainty as to a commercially viable product, reliance on external suppliers and development firms, fluctuations in the market prices of the Company's securities, possible future sales by the Company's shareholders of their securities, limited operating history of the Company, the development stage of the Company and its lack of revenues or earnings, fluctuations of our financial results, the possibility that the Company is not able to maintain its "foreign private issuer" status, and the possibility of delisting from the NASDAQ or TSX.

Please also refer to the risk factors set forth starting on page 16 of the Company's Annual Information Form for the 2017 fiscal year, available on SEDAR at www.sedar.com, which are expressly incorporated by reference into the MD&A.

There may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results or otherwise. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. Accordingly, investors should not place undue reliance on forward-looking statements.

History and Business

The Company is the successor corporation formed pursuant to two separate amalgamations under the *Business Corporations Act* (Ontario) on July 28, 2008. Titan does not have any subsidiaries.

The address of the Company's corporate office and its principal place of business is 170 University Avenue, Suite 1000, Toronto, Ontario, Canada M5H 3B3.

Overall Performance

The Company's business is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery ("MIS"). The Company is currently developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides the surgeon with an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures. The Company intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

Development of the SPORT Surgical System has proceeded in response to interviews with surgeons and operating room staff experienced in minimally invasive surgery and, consultation with medical technology development firms and input from the Company's Surgeon Advisory Board (the "Surgeon Advisory Board") comprised of key opinion leaders in targeted fields. This approach has allowed the Company to design a robotic surgical system that is intended to include the traditional advantages of robotic surgery, including 3D stereoscopic imaging and restoration of instinctive control, as well as new and enhanced features, including an advanced surgeon workstation incorporating a 3D high definition display providing a more ergonomically friendly user interface and a patient cart with enhanced instrument dexterity. Overall, the surgical system is designed to be adapted to the needs of the surgeon, rather than the surgeon having to adapt to the system.

The SPORT Surgical System patient cart is being developed to deliver interactive multi-articulating instruments and a 3D high definition vision system into a patient's abdominal body cavity through a single access port. The design of the patient cart includes an insertion tube of approximately 25 millimeter (mm) diameter. The insertion tube includes a collapsible distal end portion incorporating a 3D high definition camera module that once inserted, is configured to deploy into a working configuration wherein the camera module and multi-articulating instruments can be controlled by a surgeon via the workstation. The reusable multi-articulating, snake-like instruments are designed to couple with sterile detachable single patient use robotic end effectors that would provide first use quality in every case and eliminate the reprocessing of the complete instrument. The use of reusable (for a specific number of uses) robotic instruments and single patient use end effectors is intended to minimize the cost per procedure without compromising surgical performance. The patient cart is also designed to include a mast, a boom and wheels for optimal configurability for a variety of surgical indications and the ability to be maneuvered within the operating room, or redeployed within hospitals and surgical centers, where applicable.

As part of the development of the SPORT Surgical System, the Company is developing a robust training curriculum and post-training assessment tools for surgeons and surgical teams. The proposed training curriculum is planned to include cognitive pre-training, psychomotor skills training, surgery simulations, live animal and human cadaver lab training, surgical team training, troubleshooting and an overview of safety. Post-training assessment will include validation of the effectiveness of those assessment tools.

On September 18, 2018, the Company announced the successful completion of 14 core surgical skills simulation modules for use with the SPORT Surgical System surgeon workstation. The successful demonstration and delivery of these modules is a significant development in the first phase of the comprehensive surgeon training curriculum that the Company is planning for its SPORT Surgical System.

The Company continuously evaluates its technologies under development for intellectual property protection through a combination of trade secrets and patent application filings. As of September 30, 2018, the Company had ownership of 26 patents and 60 patent applications. The Company has accelerated prosecution of patents that management believes will validate the novelty of its unique technology, and in turn, will support the value of the entire franchise. Early evidence of success with this initiative has been the rapid growth of its patent portfolio from 12 issued patents at December 31, 2016 to 26 issued patents as of October 15, 2018, with recent issuances including Canadian Patent No. CA 2,982,615, titled “End Effector Apparatus for a Surgical Instrument”, U.S. Patent No. 9,925,014, titled “Actuator and Drive for Manipulating a Tool”. U.S. Patent No. 10,058,396, titled “System and Apparatus for Insertion of an Instrument Into a Body Cavity for Performing a Surgical Procedure”, Canadian Patent No. 2,913,943 titled “Articulated Tool Positioner and System Employing Same” and U.S. Patent No. 9,925,014 titled “Actuator and Drive For Manipulating a Tool”. The Company anticipates further expanding its patent portfolio by filing additional patent applications as it progresses in the development of robotic surgical technologies and potentially, by licensing suitable technologies.

As part of its development and commercialization efforts, the Company has established certain milestones that it uses to assess its progress towards developing commercially viable robotic surgical technologies. These milestones relate to technology and design advancements as well as to targeted dates for preclinical studies and completion of regulatory submissions. To assess progress, the Company regularly tests and evaluates its technology. If such evaluations indicate technical defects or failure to meet cost or performance goals, the Company’s commercialization schedule could be delayed and potential purchasers of its initial commercial systems may decline to purchase them or may choose to purchase alternative technologies.

Among other things, the future success of the Company is substantially dependent on continuing its research and development program, including the ongoing support of any outsourced research and development suppliers.

In addition to being capital intensive, research and development activities relating to the sophisticated technologies that the Company is developing are inherently uncertain as to future success and the achievement of desired results. If delays or problems occur during the Company's ongoing research and development activities, important financial and human resources may need to be diverted toward resolving such delays or problems. Further, there is material risk that the Company's research and development activities may not result in a functional, commercially viable product or one that is approved by regulatory authorities.

The Company achieved all of its milestones for the year ended 2017 as published in the Company's Annual Information Form for the 2017 fiscal year, including the finalization of user requirements for its first-generation robotic surgical system and selection of strategic facilities for preclinical studies in the US and Europe. The first unit was installed at Florida Hospital Nicholson Center in September 2017, followed by the installation of units at Columbia University Medical Center and Institut Hospitalo Universitaire de Strasbourg (IHU) in the fourth quarter of 2017. The Company also successfully completed all planned preclinical studies in 2017.

During the first nine months of 2018, the Company proceeded to complete its stated milestones: (1) the planning of software development and product upgrades including improvements to the workstation, patient cart, instruments, camera, light source and disposable components; (2) demonstration of the first two modules of its simulation software; (3) prototyping, testing and procurement of surgeon feedback on revised workstation controls; (4) completion of software and hardware change requirements and finalization of computer and software architecture for production systems; (5) completion of revisions to instrument and lens wash system and demonstration of performance; (6) completion of Camera Insertion Tube engineering confidence build based on improved design; (7) completion of design of SPORT Surgical System workstation and patient cart for engineering confidence build; and (8) completion and demonstration of full suite of simulation software for beta test. In addition, the Company recently achieved a significant milestone that had originally been planned for the second quarter of 2019. The achievement of that milestone, "Submit draft protocols to FDA in Q-submission(s) for comment", and the associated responses from FDA, are expected to clarify the least burdensome pathway for securing regulatory clearance in the U.S.

As previously announced, the Company has selected three Centers of Excellence (strategic facilities) for preclinical studies in the U.S. and Europe, which are:

- Florida Hospital Nicholson Center in Celebration, Florida;
- Columbia University Medical Center in New York, New York; and
- Institut Hospitalo-Universitaire de Strasbourg ("IHU Strasbourg") in Strasbourg, France.

Ahead of its published milestone, on September 25, 2017, the Company announced the completion of the world's first gynecologic, colorectal and urologic single port robotic procedures using its advanced prototype SPORT Surgical System at the Florida Hospital Nicholson Center in Celebration, Florida. Since that time, the Company has announced that surgeons have completed critical surgical tasks integral to gynecologic procedures using an advanced prototype SPORT Surgical System at Columbia University Medical Center's surgical simulation center in New York, New York, and then, the use of our SPORT Surgical System at the Institute of Image-Guided Surgery at IHU Strasbourg.

To date, 12 experienced robotic surgeons from three continents have performed 43 live animal studies and two human cadaver studies. The studies performed include a broad array of procedures commonly performed by urologic, gynecologic, colorectal, bariatric, and general surgeons. The surgeons who performed these studies have begun to prepare and submit related abstracts for peer review and presentation at clinical education meetings, including:

1. **Multi-disciplinary applications of a new robotic platform** by Barbara Seeliger, MD and Lee Swanstrom, MD (IHU Strasbourg), accepted and presented as a poster at the Society of American Gastrointestinal and Endoscopic Surgeons Meeting, Seattle, WA. (April 2018);
2. **Single-port prostatectomy using SPORT Surgical System** by Eric Barret, MD (IMM, France), accepted and presented as a poster at the EAU Section of Urology Technology Meeting, Modena, Italy, (May 2018);
3. **Multispecialty single port robotic technology applied in the live animal model: proof of concept** by Travis Rogers, MD, Eduardo Parra Davila, MD, Vipul Patel, MD (all from Florida Hospital), Ricardo Estape, MD (South Miami GOG) and Armando Melani, MD (IRCAD Brazil), accepted and presented as a poster at the Society of Robotic Surgery Meeting, Stockholm, Sweden (June 2018);
4. **Feasibility of single-port partial nephrectomy using SPORT surgical system** by Eric Barret, MD (IMM, France), accepted and presented as a poster at Society of Robotic Surgery Meeting, Stockholm, Sweden (June 2018);
5. **Single-port robotic partial and hemi nephrectomy using a novel single port robotic platform** by Sebastien Crouzet, MD (University of Lyon, France) and Barbara Seeliger, MD (IHU Strasbourg), accepted and presented at EAU Robotic Urology Section Meeting, Marseille, France (September 2018);
6. **Reverse Objective Structured Assessment of Technical Skills (Reverse-OSATS) as a means of measuring the capability of the Titan Medical SPORT Surgical System on core surgical principles** by Chetna Arora, MD, Arnold P. Advincula, MD (both from Columbia University Medical Center) and William B. Burke, MD (Stony Brook Cancer Center), accepted and presented at Society of European Robotic Gynecologic Surgeons Meeting, Milan, Italy (September 2018);
7. **Multispecialty single port robotic technology applied in the live animal model: proof of concept** by Travis Rogers, MD, Eduardo Parra Davila, MD, Vipul Patel, MD (all from Florida Hospital), Ricardo Estape, MD (South Miami GOG) and Armando Melani, MD (IRCAD Brazil), accepted and presented at World Congress of Endourology Meeting, Paris, France (September 2018); and
8. **Reverse Objective Structured Assessment of Technical Skills (Reverse-OSATS) as a means of measuring the capability of the Titan Medical SPORT Surgical System on core surgical principles** by Chetna Arora, MD, Arnold P. Advincula, MD (both from Columbia University Medical Center) and William B. Burke, MD (Stony Brook Cancer Center), accepted at American Association of Gynecologic Laparoscopists World Congress, Las Vegas, NV (November 2018).

Discussion of Operations

The Company incurred a net and comprehensive loss of \$7,534,456 and \$14,228,570 during the three and nine months ended September 30, 2018, compared with a net and comprehensive loss of 13,902,817 and \$20,757,004 for the three and nine months ended September 30, 2017. This decrease in net and comprehensive loss for the nine month period compared to the same period in 2017 is primarily attributed to a large loss from the change in fair value of warrants in 2017 compared to a gain in 2018, which was offset by higher research and development expenditures in 2018 compared to 2017. In addition, foreign exchange (gain) or loss in the three and nine months ended September 30, 2018, was \$286,152 and \$(646,245), compared to a loss of \$194,157 and \$274,721 for the comparable periods in 2017. These changes in foreign exchange of \$(91,995) and \$920,966 for the periods, are attributed primarily to the change in foreign exchange on warrant liabilities.

During the three and nine months ended September 30, 2018, corporate efforts were ongoing related to furthering strategic product development and manufacturing relationships, carrying on efforts to secure the Company's intellectual property through the patent and licensing process, and continuing the development of the Company's robotic surgical system.

Research and development expenditures (all of which were expensed in the period) for the three and nine months ended September 30, 2018 and September 30, 2017, respectively, were as follows:

Research and Development Expenditures	Three Months Ended September 30, 2018	Nine Months Ended September 30, 2018	Three Months Ended September 30, 2017	Nine Months Ended September 30, 2017
Intellectual property development	\$2,327	\$12,212	\$5,000	\$15,000
License and royalties	-	-	-	5,000
Product development	9,141,660	18,652,124	4,056,695	9,692,072
Total	\$9,143,987	\$18,664,336	\$4,061,695	\$9,712,072

Research and development expenditures increased in the nine months ended September 30, 2018 compared to the same period in 2017. This increase was primarily due to an increase in available funding in 2018 compared to 2017.

Excluding foreign exchange, general and administrative expenses for the three and nine months ended September 30, 2018, were \$1,707,084 and \$5,240,529, compared to \$1,472,795 and \$4,475,532, respectively, for the comparable periods in 2017. The increases in general and administrative expenses during both periods is attributed primarily to an increase in stock-based compensation, insurance, consulting fees and management and administrative salaries.

The gain attributed to the change in fair value of warrants for the three and nine months ended September 30, 2018 was \$4,075,833 and \$9,928,944 compared to loss of \$8,099,030 and \$5,726,557 for the same periods at September 30, 2017. The change in gain of \$12,174,863 and \$15,655,501 for the three and nine months ended September 30, 2018 reflect a decrease in the fair value of warrants in 2018 compared to 2017.

The Company realized \$93,894 and \$176,877 of interest income on its cash and cash-equivalent balances during the three and nine month periods ended September 30, 2018, and \$3,356 and \$8,764 in the three and nine months ended September 30, 2017. This increase in interest income is primarily attributed to substantially higher cash balances in the money market account in 2018 compared to 2017.

For a discussion with regard to the status of the development of the SPORT Surgical System, please see "Development Objectives" below.

Summary of Quarterly Results

The following is selected financial data for each of the eight most recently completed quarters, derived from the Company's financial statements and calculated in accordance with IFRS. Basic and diluted loss per share figures are calculated on the basis of the 30:1 consolidation of common shares.

	Three Months Ended September 30, 2018	Three Months Ended June 30, 2018	Three Months Ended March 31, 2018	Three Months Ended December 31, 2017	Three Months Ended September 30, 2017	Three Months Ended June 30, 2017	Three Months Ended March 31, 2017	Three Months Ended December 31, 2016
Net sales	-	-	-	-	-	-	-	-
Net and Comprehensive Loss (gain) from operations	\$7,534,456	\$5,885,415	\$808,699	\$12,829,980	\$13,902,817	\$1,865,913	\$4,988,274	\$2,008,365
Basic and diluted loss per share	\$0.41	\$0.47	\$0.07	\$1.20	\$1.80	\$0.30	\$0.90	\$0.30

Significant changes in key financial data from the three months ended December 30, 2016 to the three months ended September 30, 2018 reflect the ongoing development of the SPORT Surgical System. Also included is the requirement to revalue the Company's warrant liability at fair value, with subsequent changes recorded through net and comprehensive loss for the period.

Liquidity and Capital Resources

The Company currently does not generate any revenue or income (other than interest income on its cash balances) and accordingly, it is (and it will be for the foreseeable future) dependent primarily upon equity financing for any additional funding required for development and operating expenses.

The ability of the Company to arrange such financing in the future will depend in part upon prevailing capital market conditions and the business success of the Company. There can be no assurance that the Company will be successful in its efforts to arrange additional financing on terms satisfactory to the Company. If additional financing is raised by the issuance of shares or convertible securities from treasury, control of the Company may change and shareholders may suffer additional dilution. If adequate funds are not available, or are not available on acceptable terms, the Company may not be able to take advantage of opportunities, or otherwise to continue its technology development program at its current pace.

The Company had \$29,230,819 of cash and cash equivalents on hand and accounts payable and accrued liabilities of \$4,439,591 excluding warrant liability, at September 30, 2018, compared to \$26,130,493 and \$2,218,352 respectively, at December 31, 2017. The Company's working capital as at September 30, 2018 was \$29,817,770 excluding warrant liability, compared to \$26,675,319 at December 31, 2017.

Below is a table that sets out the various series of Titan warrants that were previously issued, using historic rates. The disclosure of the potential proceeds in the last column of the table below assumes all warrants are exercised on or before the expiry date. However, there is no assurance that any warrants will be exercised prior to their expiry. The chart has been updated to reflect the number of warrants issued and outstanding post 30:1 consolidation as at June 30, 2018.

	Issue Date	Expiry Date	Number Issued	Number Outstanding	Exercise Price (CDN \$)	Potential Proceeds (CDN \$)
TMD.WT.F	November 16, 2015	November 16, 2020	233,740	233,740	\$48.00	11,219,520
TMD.WT.G	February 12, 2016	February 12, 2021	389,027	386,694	\$30.00	11,600,820
TMD.WT.G	February 23, 2016	February 12, 2021	58,226	58,226	\$30.00	1,746,780
TMD.WT.H	March 31, 2016	March 31, 2021	501,831	501,831	\$36.00	18,065,916
TMD.WT.H	April 14, 2016	March 31, 2021	75,275	75,275	\$36.00	2,709,900
TMD.WT.I	September 20, 2016	September 20, 2021	569,444	569,444	\$22.50	12,812,490
TMD.WT.I	October 27, 2016	September 20, 2021	67,667	67,667	\$22.50	1,522,508
NOT LISTED	March 16, 2017	March 16, 2019	357,787	135,824	\$12.00	1,629,888
NOT LISTED	March 16, 2017	March 16, 2021	357,787	355,253	\$15.00	5,328,795
NOT LISTED	June 29, 2017	June 29, 2022	1,612,955	75,810	\$6.00	454,860
NOT LISTED	July 21, 2017	June 29, 2022	370,567	370,567	\$6.00	2,223,402
NOT LISTED	August 24, 2017	August 24, 2022	563,067	563,067	\$6.00	3,378,402
NOT LISTED	December 5, 2017	December 5, 2022	1,533,333	1,533,333	\$18.00	27,599,994
NOT LISTED	April 10, 2018	April 10, 2023	1,126,665	1,126,665	\$10.50	11,829,983
NOT LISTED	May 10, 2018	April 10, 2023	168,889	168,889	\$10.50	1,773,335
*NOT LISTED	August 10, 2018	August 10, 2023	7,679,574	7,679,574	\$4.15	31,870,232
TOTAL			15,665,834	13,901,859		145,766,825

*The exercise price of the August 10, 2018 warrants is US \$3.20. For conformity because the other warrants in this table are in CDN dollars, the exercise price and potential proceeds in respect of the August 10, 2018 warrants have been converted to CDN dollars using the Bank of Canada rate on August 3, 2018 of US \$1.00 = CDN \$1.2983.

Development Objectives

The Company uses a combination of internal resources and external development firms to execute the research, development and commercialization plan for the Company's robotic surgical system.

The results achieved by surgeons in operating prototypes in animal and cadaver studies during 2017 validated the potential for single incision surgeries to be performed with the SPORT Surgical System. However, the studies also confirmed that improvements to the system would be necessary before proceeding toward regulatory clearance and commercialization. Accordingly, product development has been accelerated in 2018 in preparation for manufacturing, including hardware and software development at all levels, involving the workstation, patient cart, camera and light source, instruments, and disposable components that facilitate successful surgery. Product improvements are expected to be completed and implemented in a capital equipment engineering confidence build of an improved prototype by year-end 2018, to be followed by system performance evaluation in early 2019.

This work will be completed before design freeze and proceeding with summative evaluation usability tests with the final product and validation studies required for regulatory filings. Based on the scope of product development ahead, the Company expects these tests and studies to take place in 2019, with the system in its final configuration and with training programs in place for new surgeon users.

A complete estimate of the timing and costs for development milestones beyond 2018 is speculative. The Company estimates that a minimum of US \$52 million, in addition to the cash and cash equivalents on hand, including deposits with suppliers, as at September 30, 2018, will be required to achieve commercialization as projected in mid-2020. This includes the capital resources necessary for the Company to submit its 510(k) application to the Food and Drug Administration of the United States Department of Health and Human Services (the "FDA"), apply for CE Marking which indicates that a product for sale within the European Economic Area (EEA) has been assessed to conform with health safety and environmental protection requirements, and if successful with those efforts, proceed with early commercialization activities. Given the uncertainty of, among other things, product development timelines, regulatory processes and requirements (such as live animal and human cadaver studies and confirmatory human studies), as well as the availability of required capital to fund development and operating costs, actual costs and development times may exceed management's current expectations and an accurate estimate of the future costs of the regulatory phases and development milestones beyond 2019 is not possible at this time.

The Company's current plan is to raise sufficient financing and continue the development and commercialization of the SPORT Surgical System at estimated incremental costs, and according to the timeline, as set forth in the table below.

Current Development Plan

The Company anticipates development costs through to the fourth quarter of 2019 to be as set out in the table below (the "Current Development Plan").

Milestone Number	Development Milestones	Estimated Cost (in U.S. million \$)	Schedule for Milestone Completion	Comments
Milestone 1	Prototype, test and procure surgeon feedback on revised workstation controls Complete software and hardware change requirements and finalize computer and software architecture for production systems Complete revisions to instrument and lens wash system and demonstrate performance		Q2 2018	<i>Completed</i>
Milestone 2	Complete Camera Insertion Tube (CIT) engineering confidence build based on improved design Complete design of SPORT Surgical System surgeon workstation and patient cart for engineering confidence build Complete and demonstrate full suite of simulation software for beta test		Q3 2018	<i>Completed</i>
Milestone 3	Complete SPORT Surgical System capital equipment engineering confidence build based on improved design	13.6 ⁽¹⁾	Q4 2018	
Milestone 4	Document results of confidence build unit testing, implement subsystem design improvements and schedule preliminary audit of quality system by European Notified Body	14.2 ⁽²⁾	Q1 2019	
Milestone 5	Update system design and related hardware and software documentation	14.4 ⁽³⁾	Q2 2019	
	Submit draft protocols to FDA in Q-submission(s) for comment			<i>Completed</i>
Milestone 6	Initiate SPORT Surgical System Design Freeze	14.3 ⁽⁴⁾	Q3 2019 –	
Milestone 7	Verify production system operation with clinical experts under rigorous formal (summative) human factors evaluation under simulated robotic manipulation exercises and through exercises of the completed surgeon simulation software and training program Complete and document preclinical live animal (swine), cadaver surgery and human confirmatory studies according to final protocols for FDA submittal Obtain ISO 13485 Certification Submit technical file to European Notified Body for review for CE Mark Submit 510(k) application to FDA	13.4 ⁽⁵⁾	Q4 2019	
	TOTAL	69.9		

Notes:

- (1) Includes research and development costs estimated at approximately US \$12.4 million, and general and administrative costs estimated at approximately US \$1.2 million.
- (2) Includes research and development costs estimated at approximately US \$12.7 million, and general and administrative costs estimated at approximately US \$1.5 million.
- (3) Includes research and development costs estimated at approximately US \$13.0 million, and general and administrative costs estimated at approximately US \$1.4 million.
- (4) Includes research and development costs estimated at approximately US \$12.8 million, and general and administrative costs estimated at approximately US \$1.5 million.
- (5) Includes research and development costs estimated at approximately US \$11.9 million, and general and administrative costs estimated at approximately US \$1.5 million.

Upon completion of the development of the SPORT Surgical System and following receipt of all applicable regulatory clearances in the United States and Europe, the Company intends to utilize a direct sales force and/or distribution partner(s) to initiate marketing of the SPORT Surgical System to hospitals.

Due to the nature of technology research and development, there is no assurance that these objectives will be achieved, and there can be no assurance with respect to the time or resources that may be required. The Company expects that additional specific milestones could be identified as the development of its SPORT Surgical System progresses, or existing milestones, budgets and the schedule for completion of each milestone may change depending on a number of factors including the results of the Company's development program, clarification of or changes to regulatory requirements, the availability of financing and the ability of development firms engaged by the Company to complete work assigned to them. The total costs to complete the development of the Company's SPORT Surgical System as referenced above are only an estimate based on current information available to the Company and cannot yet be determined with a high degree of certainty, and the costs may be substantially higher than estimated. Please see "*Forward-Looking Statements*".

Please also refer to the risk factors set forth starting on page 16 of the Company's Annual Information Form for the 2017 fiscal year, available on SEDAR at www.sedar.com.

Financings

On June 19, 2018 a share consolidation, on the basis of 30 pre-consolidation common shares forming one post-consolidation common share, was completed and the Company's outstanding common shares ("Common Shares") were adjusted from 419,888,250 to 13,996,275. All references to Common Shares, warrants, and stock options have been updated in the notes to reflect the 1:30 share consolidation.

Offerings During Q3 2018

On August 10, Titan Completed an offering of securities made pursuant to an agency agreement dated August 7, 2018 between the Company and Bloom Burton Securities Inc. ("Bloom Burton"). The Company sold 7,679,574 units under the offering price of \$2.50 per unit for gross proceeds of approximately \$19,198,935 (\$17,470,398 net of closing cost including cash commission of \$1,343,925). Each unit consisted of one Common Share of the Company and one Common Share purchase warrant, each warrant entitling the holder to acquire one Common Share at an exercise price of \$3.20 and expiring August 10, 2023.

Offerings During Q2 2018

On April 10, 2018 Titan completed an offering of securities pursuant to an agency agreement dated April 3, 2018 between the Company and Bloom Burton. The Company sold 1,126,665 units under the offering at a price of CDN \$9.00 per unit for gross proceeds of approximately \$8,035,941 (\$7,211,320 net of closing costs including cash commission of \$562,516). Each unit consisted of one Common Share and one warrant, each warrant entitling the holder thereof to acquire one Common Share at an exercise price of CDN \$10.50 and expiring April 10, 2023.

On May 10, 2018 Titan announced the exercise of the over-allotment option granted to Bloom Burton as agent for its offering, at a price of CDN \$9.00 per unit, completed on April 10, 2018 and the Company sold an additional 168,889 units at the offering price for additional gross proceeds of \$1,189,856 (\$1,100,238 net of closing costs including cash commission of \$76,988). Each unit consisted of one Common Share of the Company and one warrant, each warrant entitling the holder thereof to acquire one Common Share at an exercise price of CDN \$10.50 and expiring April 10, 2023.

Offerings During Q4 2017

On December 5, 2017 Titan completed an offering of units (the "December Offering") made pursuant to an agency agreement dated November 30, 2017 between the Company and Bloom Burton. The Company sold 1,533,333 units under the December Offering at a price of CDN \$15.00 per unit for gross proceeds of approximately \$18,137,800 (\$16,555,875 net of closing costs including cash commission of \$1,246,185 paid in accordance with the terms of the agency agreement). Each unit consisted of one Common Share and one warrant, each warrant entitling the holder thereof to acquire one additional Common Share at an exercise price of CDN \$18.00 and expiring December 5, 2022.s

On October 20, 2017 and October 30, 2017, the Company completed a non-brokered private placement offering of 446,197 Common Shares, for aggregate gross proceeds of \$2,677,326 (CDN\$3,343,416), to subscribers in Canada, the United States and Europe.

Offerings During Q2 and Q3 2017

On June 29, 2017, the Company completed an offering of securities (the “June Offering”) pursuant to an agency agreement (the “June Agency Agreement”) dated June 26, 2017 between the Company and Bloom Burton. At the first closing of the June Offering on June 29, 2017, the Company sold 1,612,955 units at a price of CDN \$4.50 per unit for gross proceeds of approximately \$5,576,357 (\$4,838,002 net of closing costs including cash commission of \$382,689 paid in accordance with the terms of the June Agency Agreement). Each unit consisted of one Common Share and one warrant, each warrant entitles the holder thereof to acquire one common share at an exercise price of CDN \$6.00 and expires June 29, 2022. In addition to the cash commission paid to Bloom Burton and selling group members, broker warrants were issued to Bloom Burton and selling group members, which entitle the holder to purchase 109,533 Common Shares at a price of CDN \$4.50 per share prior to expiry on June 29, 2019.

On July 21, 2017 Titan completed the second closing of the June Offering pursuant to which the Company sold an additional 370,567 units at a price of CDN \$4.50 per unit for gross proceeds of approximately \$1,328,871 (\$1,200,788 net of closing costs including cash commission of \$93,021 paid in accordance with the terms of the June Agency Agreement). Each unit consisted of one Common Share and one warrant, each warrant entitles the holder thereof to acquire one Common Share at an exercise price of CDN \$6.00 and expiring June 29, 2022.

Pursuant to the June Agency Agreement, in addition to the cash commission paid to Bloom Burton and the selling group members, broker warrants were issued to Bloom Burton and the selling group members, which entitle the holder to purchase 25,940 Common Shares at a price of CDN \$4.50 per share prior to expiry on June 29, 2019.

Offerings During Q1 2017

On March 16, 2017, Titan completed an offering (the “March Offering”) of securities made pursuant to an agency agreement dated March 10, 2017 (the “March Agency Agreement”) between the Company and Bloom Burton. The Company sold 715,573 units under the Offering at a price of CDN\$10.50 per unit for gross proceeds of approximately \$5,642,537 (\$5,039,817 net of closing cost including cash commission of \$394,316 paid in accordance with the terms of the March Agency Agreement). Each unit consisted of one Common Share and (i) one-half of one warrant, each whole warrant entitling the holder thereof to acquire one Common Share of the Company at an exercise price of CDN \$12.00 and expiring March 16, 2019, and (ii) one-half of one warrant, each whole warrant entitling the holder thereof to acquire one common share at an exercise price of CDN \$15.00 and expiring March 16, 2021.

Pursuant to the March Agency Agreement, in addition to the cash commission paid to Bloom Burton, broker warrants were issued to Bloom Burton which entitle the holder to purchase 50,005 common shares at a price of CDN \$10.50 per share prior to expiry on March 16, 2019.

Private Placements - Longtai Medical Inc.

On August 24, 2017, Titan completed a subscription agreement with Longtai Medical Inc. (“Longtai”) for the equity conversion of Longtai’s \$2.0 million distribution deposit. Under the terms of the subscription agreement dated July 31, 2017, Titan issued to Longtai 563,067 units at an assigned issue price of CDN \$4.50 per unit. Each unit consists of one Common Share and one warrant, with each warrant exercisable for one Common Share at an exercise price of CDN \$6.00 per warrant prior to expiry on August 24, 2022. The warrants were valued at \$822,372 based on the value of comparable warrants at the time. The common shares were valued at \$1,887,411 based on the market value on August 24, 2017 of CDN \$4.20. In addition, because the warrant and the Common Share were valued at fair value in accordance with International Financial Reporting Interpretations Committee Interpretation #19-Extinguishing Financial Liabilities (“IFRIC 19”), a loss of \$709,782 was incurred on extinguishment which is included in the gain (Loss) on change in value of warrant liability in the unaudited condensed statement of net and comprehensive loss.

Off-Balance Sheet Arrangements

Other than for leased premises occupied by the Company, the Company does not utilize off balance sheet arrangements.

Outstanding Share Data

The following table summarizes the outstanding share capital as of the date of this MD&A:

Type of Securities	Number of Common Shares issued or issuable upon conversion
Common Shares	21,675,849
Stock options ⁽¹⁾	890,361
Warrants	13,901,859
Broker warrants ⁽²⁾	790,920

Notes:

- (1) The Company has outstanding options enabling certain employees, directors, officers and consultants to purchase Common Shares. Please refer to note 4(b) of the Interim Financial Statements for terms of such options.
- (2) Pursuant to the agency agreement in respect of the March 2017 offering, in addition to the cash commission paid to the agents, 50,005 broker warrants were issued to the agents. Each broker warrant entitles the holder thereof to acquire one Common Share at the price of CDN \$10.50 for a period of 24 months following the closing date.

Pursuant to the agency agreement in respect of the June 2017 offering, in addition to the cash commission paid to the agents, 135,473 broker warrants were issued to the agents. Each broker warrant entitles the holder thereof to acquire one Common Share at the price of CDN \$4.50 for a period of 24 months following the closing date.

Pursuant to the agency agreement in respect of the December 2017 offering, in addition to the cash commission paid to the agents, 105,350 broker warrants were issued to the agents. Each broker warrant entitles the holder thereof to acquire one Common Share at the price of CDN \$15.00 for a period of 24 months following the closing date.

Pursuant to the agency agreement in respect of the April 2018 offering, in addition to the cash commission paid to the agents, 89,795 broker warrants were issued to the agents. Each broker warrant entitles the holder thereof to acquire one Common Share at the price of CDN \$9.00 for a period of 24 months following the closing date.

Pursuant to the agency agreement in respect of the August 2018 offering, in addition to the cash commission paid to the agents, 537,570 broker warrants were issued to the agents. Each broker warrant entitles the holder thereof to acquire one Common Share at the price of CDN \$2.50 for a period of 24 months following the closing date.

A total of 961,780 broker warrants were issued in connection with the March 2017, June 2017, December 2017 April 2018, and August 2018 offerings. As of the date hereof, 790,920 broker warrants remain outstanding.

Accounting Policies

The accounting policies set out in the notes to the unaudited condensed interim financial statements have been applied in preparing the unaudited condensed interim financial statements for the three and nine months ended September 30, 2018, and the comparative information presented in the unaudited condensed interim financial statements for the three and nine months ended September 30, 2017.

The preparation of financial statements in conformity with IAS 34 requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of provisions at the date of the financial statements and the reported amount of expenses during the period. Financial statement items subject to significant judgement include, (a) the measurement of stock based compensation and (b) the fair value estimate of the initial measurement of new warrant liabilities. While management believes that the estimates and assumptions are reasonable, actual results may differ.

(a) Stock Options

The Black-Scholes model used by the Company to determine fair values of stock options and warrants was developed for use in estimating the fair value of the stock options and warrants. This model requires the input of highly subjective assumptions including future stock price volatility and expected time until exercise. Changes in the subjective input assumptions can materially affect the fair value estimate.

(b) Warrant Liability

In accordance with IAS 32, because the exercise price of new warrants are not a fixed amount, they are denominated in a currency (Canadian dollar) other than the Company's functional currency (U.S. dollar), as well as the warrants issued August 10, 2018 with the cashless exercise option. The warrants are accounted for as a derivative financial liability. The warrant liability is initially measured at fair value and subsequent changes in fair value are recorded through Net and Comprehensive Loss for the period. The accounting guidance for fair value measurements prioritizes the inputs used in measuring fair value into the following hierarchy:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are directly or indirectly observable;

Level 3 – Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

The fair value of our Warrant liability is initially based on level 2 (significant observable inputs) and at September 30, 2018 is based on level 1, quoted prices (unadjusted) in an active market, for our listed warrants and level 2 for our unlisted warrants.

Related Party Transactions

During the three and nine months ended September 30, 2018, transactions between the Company and directors, officers and other related parties were related to compensation matters in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities, warrant liability, and other liabilities and charges. The fair value of these financial instruments approximates their carrying values, unless otherwise noted, due to the short term maturities of these instruments or the discount rate applied.

Outlook

During the third and fourth quarters of 2017 and early 2018, experienced robotic surgeons performed 45 single-port procedures, including 43 live porcine and two cadaver studies, at the Company's three Centers of Excellence in the US and Europe using the SPORT Surgical System. These studies validated prototype performance in preclinical settings.

During the studies, essential areas for improvement of the surgical system were identified. These include enhancements to the camera and light source, hand controls, instruments, the mechanisms of the patient cart and software throughout the system to ensure safe and reliable system operation. The final design is intended to address performance and usability requirements of prospective surgeon customers, as well as the needs of operating room support personnel and hospital administrators. Management believes that the Company is on schedule to complete a planned SPORT capital equipment engineering confidence build based on the improved design by year-end 2018.

In the first quarter of 2019, the Company plans to complete and document the results of confidence build unit testing, implement subsystem design improvements, and schedule the preliminary audit of the Company's quality system by a European Notified Body.

Throughout the balance of 2018 and through mid-year 2019, management plans to continue to focus on product development for manufacturing, including hardware and software at all levels, involving the workstation, patient cart, instruments, camera and light source, and disposable components that facilitate successful surgery.

As improvements are made to the system, advanced prototypes will be upgraded and deployed at the Centers of Excellence for further preclinical evaluation in live animal and cadaver studies to ensure that the improvements are effective. This work must be completed before freezing the design and proceeding with summative evaluation usability tests with the final product, and validation studies required for regulatory filings. Based on the scope of product development ahead, validation studies required for regulatory filings are expected to take place during the fourth quarter of 2019.

In preparation for its planned FDA 510(k) application, the Company has already filed several Q-Submissions with the FDA to clarify in detail the preclinical studies and confirmatory human data required to support its submission. The associated Q-Submission milestone has been achieved well in advance of an earlier projection for completion in 2019. The Company plans to design and execute its studies based on the FDA's responses, with the intent of filing a fully compliant 510(k) application.

Over the next twelve months, the Company plans to raise additional capital to finance the development and commercialization of the SPORT Surgical System. The company will continue to explore alternative sources in order to minimize dilutive effects, including strategic partnerships, private placements and debt. Management will continue to assess the reasonableness of development milestones, as well as timelines and related cost estimates, as financing is secured and development continues.

The Company continues to engage external technical experts and subcontractors with experience in key technical areas to provide an accelerated pathway to subsystems development with current technology. Further, the Company plans to continue to protect its intellectual property by securing additional patents. The pace at which the Company can carry out these activities will be substantially dependent on its ability to raise the necessary capital on a timely basis.

Additional information relating to the Company, including Titan's Annual Information Form for the 2017 fiscal year, is available on SEDAR at www.sedar.com.

FORM 52-109F2
CERTIFICATION OF INTERIM FILINGS
FULL CERTIFICATE

I, David McNally, Chief Executive Officer of Titan Medical Inc., certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Titan Medical Inc. (the “issuer”) for the interim period ended September 30, 2018.
 2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
 3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
 4. **Responsibility:** The issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings*, for the issuer.
 5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer and I have, as at the end of the period covered by the interim filings
 - (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
 - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
 - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
 - (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
-

- 5.1 **Control framework:** The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is Integrated Framework (COSO).
- 5.2 **ICFR – material weakness relating to design:** N/A
- 5.3 **Limitation on scope of design:** N/A
6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2018 and ended on September 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: November 13, 2018

(signed) "David McNally"

David McNally
Chief Executive Officer
Titan Medical Inc.

FORM 52-109F2
CERTIFICATION OF INTERIM FILINGS
FULL CERTIFICATE

I, Stephen Randall, Chief Financial Officer of Titan Medical Inc., certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Titan Medical Inc. (the “issuer”) for the interim period ended September 30, 2018.
 2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
 3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
 4. **Responsibility:** The issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings*, for the issuer.
 5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer and I have, as at the end of the period covered by the interim filings
 - (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
 - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
 - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
 - (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.
-

- 5.1 **Control framework:** The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is Integrated Framework (COSO).
- 5.2 **ICFR – material weakness relating to design:** N/A
- 5.3 **Limitation on scope of design:** N/A
6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2018 and ended on September 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: November 13, 2018

(signed) "Stephen Randall"

Stephen D. Randall
Chief Financial Officer
Titan Medical Inc.